http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Anti-Cancer and Radiation Protection Effects by Ganoderma Lucidum
Yeunhwa Gu,Kouri Ryutarou,Takashi Nakamura,Kenichiro Tanaka,Masayuki Tajima,Takenori Yamashita,Hiroaki Tanabe,Daigo Matsumoto,Hajime Monzen,Masami Oshima,Eunsuk Choi,Ikukatsu Suzuki,Kyoo Seok Ahn,Tets 한의병리학회 2004 대한동의병리학회 학술대회논문집 Vol.2004 No.8
Anti-Cancer and Radiation Protection Effects by Ganoderma Lucidum
Yeunhwa Gu,Kouri Ryutarou,Takashi Nakamura,Kenichiro Tanaka,Masayuki Tajima,Takenori Yamashita,Hiroaki Tanabe,Daigo Matsumoto,Hajime Monzen,Masami Oshima,Eunsuk Choi,Ikukatsu Suzuki,Kyoo Seok Ahn,Tets 한의병리학회 2004 대한동의병리학회 학술대회논문집 Vol.2004 No.8
Muneaki Shimada,Kosuke Yoshihara,Terumi Tanigawa,Hiroyuki Nomura,Junzo Hamanishi,Satoe Fujiwara,Hiroshi Tanabe,Hiroaki Kajiyama,Masaki Mandai,Daisuke Aoki,Takayuki Enomoto,Aikou Okamoto 대한부인종양학회 2023 Journal of Gynecologic Oncology Vol.34 No.3
The development of new treatments for gynecological malignancies has been conducted mainly through collaborative international phase III trials led by the United States and Europe. The survival outcomes of many gynecological malignancies have greatly improved as a result. Recent large-scale genome-wide association studies have revealed that drug efficacy and adverse event profiles are not always uniform. Thus, it is important to validate new treatment options in each country to safely and efficiently provide newly developed treatment options to patients with gynecological malignancies. The Japanese Gynecologic Oncology Group (JGOG) is conducting 5 cohort studies (JGOG 3026, 3027, 3028, 3030, and 3031) to establish real-world data (RWD) of poly(ADP-ribose) polymerase (PARP) inhibitor use in patients with advanced or recurrent epithelial ovarian cancer. The RWD constructed will be used to provide newly developed PARP inhibitors for women with advanced or recurrent ovarian cancer in a safer and more efficient manner as well as to develop further treatment options. In 2022, The JGOG, Korean Gynecologic Oncology Group, Chinese Gynecologic Cancer Society, and Taiwanese Gynecologic Oncology Group established the East Asian Gynecologic Oncology Trial Group to collaborate with East Asian countries in clinical research on gynecologic malignancies and disseminate new knowledge on gynecologic malignancies from Asia. The JGOG will conduct a collaborative integrated analysis of the RWD generated from Asian countries and disseminate real-world clinical knowledge regarding new treatment options that have been clinically implemented.